Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Myoviridae bacteriophage against Klebsiella pneumoniae (169.802 bp)
- Development stage
- Unknown
- Lead developer
- TechnoPhage
- Modality
- Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Inhalation
01
Overview
**Myoviridae bacteriophage against Klebsiella pneumoniae (169.802 bp)** is an investigational lytic bacteriophage, also designated **Kle_F58/19**, developed by Technophage for targeted treatment of *Klebsiella pneumoniae* infections. The phage infects susceptible *K. pneumoniae* cells, replicates intracellularly, and lyses the bacterial host to release progeny phage. Kle_F58/19 is one of three *K. pneumoniae*-directed phages described for the TP-122B component of Technophage's TP-122 respiratory bacteriophage program; its public development context includes ventilator-associated pneumonia. ([clinicaltrials.eu](https://clinicaltrials.eu/drug/myoviridae-bacteriophage-against-klebesiella-pneumoniae-169-802-bp/))
- Other names
- Kle_F58/19Myoviridae bacteriophage against Klebsiella pneumoniae
02
Targets
K1 CPS (Klebsiella pneumoniae capsular polysaccharide serotype K1)
Beyond the preview
Go deeper on Myoviridae bacteriophage against Klebsiella pneumoniae (169.802 bp).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Myoviridae bacteriophage against Klebsiella pneumoniae (169.802 bp).